<DOC>
	<DOCNO>NCT00399776</DOCNO>
	<brief_summary>We hypothesize antipsychotic induced hyperprolactinemia decrease bone mineral accrual decrease bone mineral content ( BMC ) adolescents antipsychotic therapy . Specifics Aims 1 . To determine antipsychotic therapy lead decrease bone mineral accrual decrease bone mineral content group adolescents antipsychotic therapy compare ethnicity , gender pubertal stage match control group . 2 . To determine relationship serum concentration prolactin , sex steroid bone turnover marker adolescent antipsychotic therapy ethnicity , gender pubertal stage match control group .</brief_summary>
	<brief_title>Bone Mineral Content Bone Metabolism Adolescents Antipsychotic Therapy</brief_title>
	<detailed_description>Recent study show increase antipsychotic prescription among child adolescent . Virtually pediatric use antipsychotic `` off-label , '' mean without Food Drug Administration indication . To make matter bad , pediatric antipsychotic usage lead serious side effect like movement disorder metabolic disturbance . Hence , concern despite virtual absence long term efficacy safety data , widespread use antipsychotic child adolescent continue . One important adverse effect antipsychotic therapy hyperprolactinemia . Prolactin hormone secrete central nervous system . The main action prolactin females induction maintenance lactation . The main action prolactin females induction maintenance lactation . Antipsychotic therapy show raise prolactin level , adult pediatric population . Sustained hyperprolactinemia cause number endocrinological abnormality lead hypogonadal state eventually bone demineralization osteoporosis . There evidence link pediatric prolactinomas decrease bone density . Also , adult study suggest high rate osteoporosis schizophrenia may result hypogonadism secondary antipsychotic induce hyperprolactinemia . Our concern sequela antipsychotic induced hyperprolactinemia child adolescent , receive little attention , despite important implication bone health . This topic especially important peak bone mass achieve adolescence key determinant lifetime risk osteoporosis . We hypothesize antipsychotic induced hyperprolactinemia interrupt bone mineral accrual reduce bone mineral content adolescent antipsychotic therapy . We plan measure bone mineral content peripheral marker bone metabolism adolescent antipsychotic therapy compare ethnicity , gender pubertal stage match control . We also plan measure serum level prolactin hormonal measure : estradiol , progesterone , testosterone , follicle stimulate hormone , luteinizing hormone thyroid function test group . Statistical analysis perform compare bone mineral content study control group . Additionally , association hormonal measure bone mineral content determine . Osteoporosis major public health problem . In United States today , 10 million individual already osteoporosis , 18 million low bone mass , place increase risk disorder . Optimization bone health process must occur throughout lifespan factor influence bone health age essential prevent osteoporosis devastate consequence . To date , publish study , examine association antipsychotic induce hyperprolactinemia bone mineral content ( BMC ) and/or risk osteoporosis child adolescent . Although report antipsychotic induce hyperprolactinemia prepubertal postpubertal child , suggest post pubertal child may high risk decrease BMC . Thus , plan initially study effect adolescent . Potential implication research finding include : providing recommendation prevent , diagnose monitor bone mineral content/density pediatric antipsychotic therapy . Since unexplored area , yet crucial field , finding study expect ramification clinical practice within one two year project completion .</detailed_description>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . Adolescent female male antipsychotic exposure equivalent least 100 chlorpromazine equivalent minimum one year . 2 . Age 10 17 year age 3 . Within 10th 90th percentile height weight 1 . Pregnant 2 . Chronic illness asthma , inflammatory bowel disease , rheumatoid disorder cystic fibrosis . 3 . On chronic systemic steroid therapy past 12 month 4 . For subject hypothyroidism thyroid replacement therapy , TSH level obtain determine eligibility . 5 . Menstrual irregularity secondary excessive physical activity . 6 . History anorexia nervosa and/or bulimia nervosa . 7 . Subjects hormonal contraception .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>bone mineral</keyword>
	<keyword>antipsychotic therapy</keyword>
	<keyword>bone mineral accrual</keyword>
	<keyword>bone mineral content</keyword>
</DOC>